Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the HER2-Negative Breast Cancer Market Growth in 2025?
The market for HER2-negative breast cancer has been enjoying robust growth in recent years. It is forecasted to rise from $16.29 billion in 2024 to $17.62 billion in 2025, representing an impressive compound annual growth rate (CAGR) of 8.1%. The development experienced in the historic period can be linked to the increase in incidences of breast cancer, elevated awareness concerning the disease, heightened expenditure on healthcare, an aging demographic, and the growth of healthcare infrastructures.
What Is the Forecast for the HER2-Negative Breast Cancer Market Size Through 2029?
The market size of HER2-negative breast cancer is anticipated to witness robust growth in the upcoming years. The industry is projected to expand to $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Various factors contributing to this projected growth through the forecast period include the upsurge in alcohol consumption, a rise in unhealthy lifestyle choices, escalating obesity rates, an increase in tobacco use, and the escalating demand for effective treatment solutions. Notable trends expected to shape the market throughout the forecast period encompass advancements in diagnostic technologies, the incorporation of targeted therapies, the amalgamation of immunotherapies, approvals from FDA, and technological progress.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp
What are the Key Market Players in HER2-Negative Breast Cancer Market and How They’re Evolving?
Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
What Are the Primary Growth Drivers in the HER2-Negative Breast Cancer Market?
The increasing number of breast cancer incidents is anticipated to boost the expansion of the HER2-negative breast cancer market in the future. Breast cancer, a condition characterized by the unchecked expansion of abnormal cells in breast tissue, typically originates from the ducts or lobules. The increasing number of breast cancer incidents can be linked to numerous elements, including heightened awareness and improved screening techniques, resulting in earlier and more consistent detection. HER2-Negative Breast Cancer plays a pivotal role in propelling breast cancer research by offering insights into unique tumor biology and treatment strategies, thereby aiding in the creation of more targeted remedies for patients. For instance, the Centers for Disease Control and Prevention, a US government agency, reported that, in the United States in June 2024, 272,454 new breast cancer cases were identified among women in 2021, while 42,211 women died from the disease in 2022. Consequently, the increasing number of breast cancer incidents is stimulating the expansion of the HER2-negative breast cancer market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp
What Are the Leading Segments in the Global HER2-Negative Breast Cancer Industry?
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
What Are the Key Market Trends in the HER2-Negative Breast Cancer Industry?
Prominent entities in the HER2-negative breast cancer market are concentrating on obtaining regulatory clearances to launch fresh treatments, broaden their product range, and upgrade their market stature. Regulatory approval implies the formal permission provided by government authorities, which permits companies to sell and disperse drugs or treatments upon fulfilling safety, efficacy, and quality criteria. For instance, in October 2024, Genentech Inc., a US-based biotech company, achieved FDA authorization for Itovebi (inavolisib), a focused treatment for advanced HR+, HER2-negative breast cancer with a PIK3CA mutation. This approval authorizes the use of Itovebi along with palbociclib and fulvestrant, thereby significantly ameliorating progression-free survival for patients as compared to traditional treatments. This novel regimen offers a crucial alternative for patients with bounded treatment options, underlining the significance of biomarker testing to pinpoint those who would benefit the most from this treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report
What Is the Regional Outlook for the HER2-Negative Breast Cancer Market?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203
This Report Delivers Insight On:
1. How big is the her2-negative breast cancer market, and how is it changing globally?
2. Who are the major companies in the her2-negative breast cancer market, and how are they performing?
3. What are the key opportunities and risks in the her2-negative breast cancer market right now?
4. Which products or customer segments are growing the most in the her2-negative breast cancer market?
5. What factors are helping or slowing down the growth of the her2-negative breast cancer market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model